Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

Translated title of the contribution: Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
  • E. Kneppers
  • , B. van der Holt
  • , M.J. Kersten
  • , S. Zweegman
  • , E. Meijer
  • , G. Huls
  • , J.J. Cornelissen
  • , J.J. Janssen
  • , C. Huisman
  • , P.B. Cornelisse
  • , C.P. Bruijnen
  • , M.E. Emmelot
  • , P. Sonneveld
  • , H.M. Lokhorst
  • , T. Mutis
  • , M.C. Minnema

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionLenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Original languageUndefined/Unknown
Pages (from-to)2413-2419
Number of pages7
JournalBlood
Volume118
Issue number9
Publication statusPublished - 2011

Cite this